acomplia acomplia acomplia
Centrex France Pharmacy
$0.00 (0 items)Checkout

Products

acomplia rimonabant
cheap acomplia buy acomplia
 
Generic AcompliaGeneric Acomplia
Category:Weight Loss
Generic:Rimonabant 20mg
Package Price Per Pill Order
20mg × 28 pills $79.95 US $ 2.86 Buy Now!
20mg × 42 pills $109.95 US $ 2.62 Buy Now!
20mg × 168 pills $288.95 US $ 1.72 Buy Now!
20mg × 252 pills $409.95 US $ 1.63 Buy Now!
 
Most popular quantity.

Acomplia (Rimonabant) is a new miraculous multifunctional diet pill called "miracle pill".

According to a report published by the Journal of the American Medical Association, Acomplia produces sustained weight loss, helps to quit smoking, improves high-density lipoprotein (HDL) cholesterol and triglyceride levels and improves blood makers.

What is Acomplia?

  • Acomplia (Rimonabant) is the new hope for overweight people and for people that have problems with their weight.
  • Acomplia ( Rimonabant) is also known as SR141716, Riobant, Slimona, Rimoslim, and Zimulti.
  • Acomplia was developed by Sanofi-aventis.

How does Acomplia work?

  • Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle.
  • Acomplia (Rimonabant or Zimulti) diet pills offer hope for obese individuals. Especially where other treatments had little affect or whose side effects where too much to handle.
  • Rimonabant Acomplia works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System) , believed to play a critical role in the regulation of food intake and energy expenditure. The receptors are present on the surfaces of many cells throughout the body, including fat cells — which are involved in lipid and glucose metabolism — and those in the hypothalamus, the brain region that is thought to determine appetite.

Does Acomplia also aid smoking cessation?

  • Acomplia has been studied by sanofi-aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking and the results were defined as Acomplia (Rimonabant) also aid smoking cessation.

What were the results of Generic Acomplia Clinical trial studies?

  • In clinical studies, Acomplia has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss4,5, but this depands on the patient because it works better with diet and exercises.
  • Acomplia is a French drug designed to quit the smoking and check obesity. It suppresses the appetite by blocking hunger signals to brain. Acomplia affects endocannabinoid system. Acomplia targets newly discovered hunger center Cannabinoid receptors in the brain thus controlling the hunger..

What are the side-effects of Acomplia?

  • Side effects in the trial on Acomplia in obesity were vomiting and nausea, forcing about 19 percent of patients to leave the trial versus 13 percent of those who took placebo. But for many others Acomplia helps.
  • Buy Acomplia, Generic Acomplia or buy Rimonabant, Centrex France offers Acomplia Rimonabant Informations
Latest Tabs News

Paris France March 08

Britain’s National Institute for Health and Clinical Excellence has given approval for Acomplia (Rimonabant). French drug maker Sanofi-Aventis said that its obesity-fighting product Acomplia (Rimonabant) had won approval from Britain's National Institute for Health and Clinical Excellence (NICE). NICE had recommended that Rimonabant (Acomplia) should be made available for the management of obese and overweight patients on the UK's state-run National Health Service.The British government has made fighting obesity, particularly among young people, one of its key priorities.

 

McAfee Safe

Moneyback Guarantee

 

Washington USA June 10

Acomplia, an weight loss drug, helps obese people with type 2 diabetes lose weight, reduce waist size, and even control blood sugar and blood fats.Surprisingly, Acomplia's beneficial effect on blood sugars and fats went 57 percent beyond the benefit that would have been expected from weight loss alone. The drug, which affects the body's cannabinoid system, appears to reduce interrelated risks for heart and metabolic diseases.The benefits seen were in addition to the benefits of standard, ongoing treatment with Glucophage or the family of diabetes drugs called sulfonylureas. Researcher André Scheen, MD, head of diabetes at the University of Liège in Belgium, reported the findings at annual meeting of the American Diabetes Association.

Sao Paulo Brazil April 26

Sanofi-aventis announced that the ANVISA, the Brazilian Health Authority, has granted marketing authorisation for ACOMPLIA®. Acomplia is indicated as an adjunct to diet and exercise for the treatment of obese patients (Body Mass Index - BMI above or equal to 30 kg/m2), or overweight patients (BMI above 27 kg/m2) with associated risk factors, such as type 2 diabetes or dyslipidemia. Acomplia (Rimonabant) is the first member of a new therapeutic class: the CB1 receptor antagonists. The marketing authorisation is based on a thorough analysis of the extensive safety and efficacy results and the assessment of the pivotal clinical trial program of the phase III. These results have shown that ACOMPLIA® at 20 mg per day (1 tablet) significantly reduces weight, waist circumference, HBA1c, triglycerides, at the same time improving significantly the patients’ HDL.

bookmark Bookmark this site
subscribe Subscribe for News
acomplia
We accept mastercard, visa.
Corner of Trust